Hohl Benjamin
CHIEF FINANCIAL OFFICER
Hohl Benjamin has filed 8 SEC Form 4 filings (43 transaction rows) across 1 company, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Aug 19, 2026.
On the most recent filing, Hohl Benjamin is listed as CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. Inside the rolling window, Hohl Benjamin reported no open-market purchases and 5 open-market sales totaling $1.3M in ELVN. The largest disclosed transaction in the window is a sale of 6,018 ELVN shares on Aug 17, 2026, worth $353K.
Companies traded
Other insiders at ELVN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.3M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Hohl Benjamin made?
Hohl Benjamin has filed 8 SEC Form 4 filings (43 transaction rows) across 1 company since 2025.
Which companies does Hohl Benjamin trade?
Hohl Benjamin has filed SEC Form 4 disclosures for 1 company, including ELVN.
When was Hohl Benjamin's most recent SEC Form 4 filing?
Hohl Benjamin's most recent SEC Form 4 filing on Tracefour is dated Aug 19, 2026.
What is Hohl Benjamin's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Hohl Benjamin is listed as CHIEF FINANCIAL OFFICER.
What is Hohl Benjamin's total buy and sell value in the current window?
Inside the rolling retention window, Hohl Benjamin bought $0 and sold $1.3M based on SEC Form 4 filings.
What was Hohl Benjamin's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,018 ELVN shares on 2026-08-17, worth $353K, per SEC Form 4 filings.